EA201791103A1 - Терапевтический гомодимер и его применения - Google Patents

Терапевтический гомодимер и его применения

Info

Publication number
EA201791103A1
EA201791103A1 EA201791103A EA201791103A EA201791103A1 EA 201791103 A1 EA201791103 A1 EA 201791103A1 EA 201791103 A EA201791103 A EA 201791103A EA 201791103 A EA201791103 A EA 201791103A EA 201791103 A1 EA201791103 A1 EA 201791103A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapeutic
homodimer
applications
relates
prophylaxis
Prior art date
Application number
EA201791103A
Other languages
English (en)
Other versions
EA034876B1 (ru
Inventor
Арпи Роджерс
Original Assignee
Арпи Роджерс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арпи Роджерс filed Critical Арпи Роджерс
Publication of EA201791103A1 publication Critical patent/EA201791103A1/ru
Publication of EA034876B1 publication Critical patent/EA034876B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Изобретение относится к терапевтическим пептидам и их применениям. В частности, изобретение относится к связанным дисульфидом гомодимерам, пригодным в лечении или профилактике у пациентов-млекопитающих заболеваний и состояний (таких как диабет) трансмукозальным введением.
EA201791103A 2014-11-18 2015-11-16 Применение пептидного гомодимера для лечения заболеваний, связанных с диабетом, путем перорального введения EA034876B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1420445.7A GB2532426B (en) 2014-11-18 2014-11-18 Therapeutic homodimer and uses thereof
PCT/EP2015/076712 WO2016079066A1 (en) 2014-11-18 2015-11-16 Therapeutic homodimer and uses thereof

Publications (2)

Publication Number Publication Date
EA201791103A1 true EA201791103A1 (ru) 2017-09-29
EA034876B1 EA034876B1 (ru) 2020-04-01

Family

ID=52248504

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791103A EA034876B1 (ru) 2014-11-18 2015-11-16 Применение пептидного гомодимера для лечения заболеваний, связанных с диабетом, путем перорального введения

Country Status (20)

Country Link
US (2) US20180015136A1 (ru)
EP (1) EP3220939B1 (ru)
JP (1) JP6693969B2 (ru)
KR (1) KR20170083064A (ru)
CN (1) CN107206048B (ru)
AU (1) AU2015348673B2 (ru)
BR (1) BR112017010346A2 (ru)
CA (1) CA2967140C (ru)
CY (1) CY1124859T1 (ru)
DK (1) DK3220939T3 (ru)
EA (1) EA034876B1 (ru)
ES (1) ES2886001T3 (ru)
GB (1) GB2532426B (ru)
HK (1) HK1223287A1 (ru)
IL (1) IL252349B (ru)
MA (1) MA40969A (ru)
MX (1) MX2017006278A (ru)
SG (1) SG11201703757PA (ru)
WO (1) WO2016079066A1 (ru)
ZA (1) ZA201703580B (ru)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0516527D0 (en) * 2005-08-11 2005-09-21 Arpi Matossian Rogers Peptides
CN105017423B (zh) * 2005-08-11 2019-06-04 阿皮·马托西安-罗杰斯 用于自身免疫性疾病治疗和诊断的TCR-V-β相关肽

Also Published As

Publication number Publication date
DK3220939T3 (da) 2021-08-30
CA2967140C (en) 2021-09-21
GB201420445D0 (en) 2014-12-31
JP2018500386A (ja) 2018-01-11
EP3220939A1 (en) 2017-09-27
MA40969A (fr) 2021-04-28
CY1124859T1 (el) 2022-11-25
AU2015348673B2 (en) 2019-01-03
ES2886001T3 (es) 2021-12-16
CN107206048B (zh) 2021-02-26
US20180015136A1 (en) 2018-01-18
SG11201703757PA (en) 2017-06-29
US20210060118A1 (en) 2021-03-04
GB2532426B (en) 2016-11-02
KR20170083064A (ko) 2017-07-17
JP6693969B2 (ja) 2020-05-13
MX2017006278A (es) 2017-10-24
EP3220939B1 (en) 2021-06-30
ZA201703580B (en) 2018-08-29
AU2015348673A1 (en) 2017-06-01
CA2967140A1 (en) 2016-05-26
IL252349B (en) 2022-02-01
IL252349A0 (en) 2017-07-31
HK1223287A1 (zh) 2017-07-28
GB2532426A (en) 2016-05-25
BR112017010346A2 (pt) 2018-05-15
WO2016079066A1 (en) 2016-05-26
CN107206048A (zh) 2017-09-26
NZ731655A (en) 2020-09-25
EA034876B1 (ru) 2020-04-01

Similar Documents

Publication Publication Date Title
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MD3370770T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
EA201890204A1 (ru) Антибактериальные соединения
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201691607A1 (ru) Микроорганоиды и способы их получения и применения
EA201692473A1 (ru) Способы получения замещенных нуклеотидных аналогов
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2017003211A (es) Anticuerpos anti-met y composiciones.
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
EA201890572A1 (ru) Биофармацевтические композиции
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
BR112017008672A2 (pt) anticorpos de il-6 melhorados
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
CL2016002839A1 (es) Derivados de carboxamida
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
CO2017005759A2 (es) Composiciones farmacéuticas de acción prolongada para la hepatitis c
EA201791103A1 (ru) Терапевтический гомодимер и его применения
MX2020006173A (es) Derivados glucosidicos de treprostinilo.